[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Maryland St. Joseph Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100555524","phase-4-ketorolac-effects-on-post-operative-pain-and-lumbar-fusion-100555524",false,"NCT06513208","Ketorolac Effects on Post-operative Pain and Lumbar Fusion","Ketorolac Effects on Post-operative Pain and Lumbar Fusion: a Double Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* 18-85 years old (inclusive)\n* Elective posterior lumbar instrumented fusion\n* One or two level fusion\n* Consent to participate in study and willing to adhere to study follow up\n* English proficiency\n\nExclusion Criteria:\n\n* \\\u003C 18 or \\> 85 years old\n* History of renal failure, dialysis, or creatinine over 1.50 mg\u002Fdl\n* Active or recent smoker (active within past 6 months)\n* Revision surgery\n* Auto\u002Fworker compensation\n* Active cancer or history of chemotherapy in past 6 months\n* Active narcotic use within 3 months of surgery date\n* Infection at operative levels\n* Any allergies to NSAIDs or Opioids",true,"ALL","18 Years","85 Years",{"count":21,"type":22},140,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","A double blind prospective randomized trial of IV ketorolac vs. placebo in management of patients undergoing lumbar one or two level spinal fusions.",[28],"Lumbar Spinal Fusion",[30,31,32],"ketorolac","toradol","lumbar spine fusion","RECRUITING","2025-12-18",{"date":36,"type":37},"2025-12-22","ACTUAL",{"date":39,"type":22},"2026-01",{"date":41,"type":22},"2027-06",{"name":43,"class":44},"University of Maryland St. Joseph Medical Center","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100553553","phase-4-ang-first-trial-angiotensin-ii-as-first-line-vasopressor-therapy-in-cardiac-surgery-100553553","NCT06487585","ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)","Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery (ANG-First Trial)","Inclusion Criteria:\n\n* Adult patients ≥ 18 years of age undergoing cardiac surgery requiring CPB\n* Patients must have clinical features of vasodilation as determined by a MAP \\\u003C 65 mmHg that is non-transient in the opinion of the treating physician\n* Patients must be adequately volume resuscitated in the opinion of the treating physician\n* Systemic Vascular Resistance index (SVRi) \\\u003C 1970 dynes·sec\u002Fcm⁵\u002Fm² to support the clinical diagnosis of vasodilation; if no pulmonary artery catheter is in place, vasodilatory hypotension diagnosis according to the judgement of the critical care team\n* Biventricular systolic function is at or greater than pre-cardiopulmonary bypass baseline as demonstrated by echocardiographic evaluation, or the patient is concomitantly treated with\n\nExclusion Criteria:\n\n* Bleeding as primary etiology of hypotension, as determined by \\> 4 units RBC transfusion in 24 hours.\n* Patients on ECMO\n* Patients with active endocarditis\n* Patients already on renal replacement therapy or creatinine of \\> 4 mg\u002Fdl within 2 weeks of surgery\n* Patients with contraindications to Angiotensin II including women who are pregnant or breastfeeding or have active coronary ischemia, mesenteric ischemia, limb ischemia, or high potassium (\\> 5.5 meq\u002FL) while receiving Angiotensin II",{"count":54,"type":22},100,[25],"The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.",[58],"Vasodilatory Hypotension During or After Cardiac Surgery",[60,61,62,63],"Vasodilation","Hypotension","Cardiopulmonary Bypass","Cardiac Surgery",{"date":36,"type":37},{"date":66,"type":37},"2025-05-06",{"date":68,"type":22},"2026-02",{"name":43,"class":44},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100561902","phase-4-spinal-cord-stimulation-for-chemotherapy-induced-peripheral-neuropathy-100561902","NCT06596200","Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy","Pilot Study for the Use of Spinal Cord Stimulation to Alleviate Pain from Chemotherapy Induced Peripheral Neuropathy Due to Taxane or Platinum Based Agents","Inclusion Criteria:\n\n* CIPN as diagnosed by Oncology and\u002For neurology\n* Receipt of a platinum-based or taxane chemotherapy prior to development of CIPN\n* Pain severity greater than 4 out of 10 on a numeric rating scale of pain\n* Pain chronicity greater than 6 months after the cessation of chemotherapy\n* Failure of medical therapy, which must have included duloxetine\n* Age 18 or greater\n\nExclusion Criteria:\n\n* Platelet count less than 100k\u002Fmm3\n* Spinal anatomy precluding placement of the SCS leads between T6 and T11\n* Active infection\n* Estimated Lifespan less than 1 year\n* Receipt of vincristine, thalidomide, bortezomib, or eribulin within the prior 12 months",{"count":78,"type":22},10,[25],"Spinal Cord Stimulation using 10 kHz stimulation to the thoracic spinal cord will be a safe and effective treatment for CIPN, reducing pain in the lower extremities by at least 50%.",[82],"Chemotherapy-induced Peripheral Neuropathy","NOT_YET_RECRUITING","2024-09-12",{"date":86,"type":37},"2024-09-19",{"date":88,"type":22},"2024-09-15",{"date":90,"type":22},"2026-11-15",{"name":43,"class":44},""]